Skip to nav Skip to content

Moffitt Cancer Center patients with myelodysplastic syndromes (MDS) aren’t cared for by just one doctor, but rather an entire multispecialty team. Our Malignant Hematology program features a team of medical oncologists, hematologists, pathologists, surgeons and other MDS doctors who specialize exclusively in MDS, and take a collaborative approach to treatment that focuses on attacking MDS from a variety of angles while comprehensively addressing our patients’ needs.     

Beyond our multispecialty team, there are several reasons why Moffitt is considered to be a worldwide leader in the evaluation, diagnosis and treatment of MDS:

  • Every MDS doctor at Moffitt has ample experience treating all forms of MDS and acute myeloid leukemia, which can develop from more aggressive cases of MDS. In fact, we have one of the largest MDS programs in the United States. This means our MDS doctors have a unique level of experience treating even the rarest forms of MDS, and this expertise translates into better outcomes and quality of life for our patients.  
  • MDS cases are regularly and carefully reviewed by Moffitt’s tumor board, which refines each patient’s individualized treatment plan according to his or her progress and specific needs.  
  • Moffitt is a National Cancer Institute-designated Comprehensive Cancer Center – the only one based in Florida. This distinction speaks directly to our commitment to molecular studies, cancer research and our robust clinical trial program, which is aimed at discovering new, innovative treatments for MDS and other malignancies.

Furthermore, patients in Moffitt’s MDS program have access to a full range of supportive care in the same location. Psychosocial counseling, side effect management, dietary advice and more are provided to our patients to help improve quality of life during the treatment process with an MDS doctor. 

check mark symbol Medically reviewed by David Sallman, MD, Malignant Hematology Program

To consult with an MDS doctor at Moffitt, contact 1-888-663-3488 or complete a new patient registration form. Referrals are not required to visit Moffitt.

  • Malignant Hematology Leadership
    Jeffrey  Lancet, MD
    Department Chair, Malignant Hematology
    Program Lead, Malignant Hematology

    Program

    Malignant Hematology

    Title

    Chair, Department of Malignant Hematology

    Specialty

    Hematology

    5 (144)
    Rami  Komrokji, MD

    Program

    Malignant Hematology

    Title

    Vice Chair, Department of Malignant Hematology

    Specialty

    Hematology/Oncology

    5 (233)
  • Myelodysplastic Syndromes (MDS) Medical Oncologists

    Meet the medical oncologists who specialize in the treatment of myelodysplastic syndromes (MDS).

    Hugo  Fernandez, MD
    Department Chair, Malignant Hematology and Cellular Therapy at Memorial Healthcare System
    Program Lead, Malignant Hematology and Cellular Therapy at Memorial Healthcare System

    Program

    Malignant Hematology and Cellular Therapy at Memorial Healthcare System

    Title

    Chair, Malignant Hematology and Cellular Therapy at Memorial Healthcare System

    Specialty

    Medical Oncology

    Eric  Padron, MD

    Program

    Malignant Hematology

    Specialty

    Medical Oncology

    4.9 (106)
    Kendra  Sweet, MD

    Program

    Malignant Hematology

    Specialty

    Medical Oncology

    4.9 (34)
    Mark  Honor, PA

    Specialty

    Medical Oncology

    4.9 (108)
  • Myelodysplastic Syndromes (MDS) Hematology Oncologists

    Meet the hematology oncologists who specialize in the treatment of myelodysplastic syndromes (MDS).

    Onyee  Chan, MD

    Program

    Malignant Hematology

    Specialty

    Hematology/Oncology

    4.9 (133)
    Deepak  Chellapandian, MD, MBBS

    Program

    Blood and Marrow Transplant and Cellular Immunotherapy

    Specialty

    Hematology/Oncology

    Yehuda  Deutsch, MD

    Program

    Malignant Hematology and Cellular Therapy at Memorial Healthcare System

    Title

    Vice Chair, Malignant Hematology and Cellular Therapy at Memorial Healthcare System

    Specialty

    Hematology/Oncology

    Jonathan  Feld, MD

    Program

    Malignant Hematology and Cellular Therapy at Memorial Healthcare System

    Specialty

    Hematology/Oncology

    Rami  Komrokji, MD

    Program

    Malignant Hematology

    Title

    Vice Chair, Department of Malignant Hematology

    Specialty

    Hematology/Oncology

    5 (233)
    Timothy  Kubal, MD, MBA
    Department Chair, MMG Ambulatory HemOnc
    Program Lead, MMG Ambulatory HemOnc

    Program

    MMG Ambulatory HemOnc

    Specialty

    Hematology/Oncology

    5 (188)
    Damian  Laber, MD

    Program

    MMG Ambulatory HemOnc

    Specialty

    Hematology/Oncology

    4.9 (94)
    Sayeef  Mirza, MD, MPH

    Program

    Blood and Marrow Transplant and Cellular Immunotherapy

    Specialty

    Hematology/Oncology

    4.8 (27)
    Reshma  Ramlal, MD

    Program

    Blood and Marrow Transplant and Cellular Immunotherapy

    Specialty

    Hematology/Oncology

    5 (33)
    Sam  Reynolds, MD

    Program

    MMG Ambulatory HemOnc

    Specialty

    Hematology/Oncology

    4.9 (258)
    David  Sallman, MD

    Program

    Malignant Hematology

    Specialty

    Hematology/Oncology

    4.9 (124)
    Jose  Sandoval Sus, MD

    Program

    Malignant Hematology and Cellular Therapy at Memorial Healthcare System

    Specialty

    Hematology/Oncology

    Rory  Shallis, MD

    Program

    Malignant Hematology

    Specialty

    Hematology/Oncology

    4.9 (173)
    Alison  Walker, MD, MPH, MBA

    Program

    Malignant Hematology

    Specialty

    Hematology/Oncology

    4.9 (120)
    Zoey  Xie, MD, MS

    Program

    Malignant Hematology

    Specialty

    Hematology/Oncology

    4.9 (117)
    Alicia  Canalejo, APRN

    Specialty

    Hematology/Oncology

    4.9 (32)
    Carolina  Leon, APRN

    Specialty

    Hematology/Oncology

    4.8 (22)
    Catherine  Quealy, APRN

    Program

    Blood and Marrow Transplant and Cellular Immunotherapy

    Specialty

    Hematology/Oncology

    Sara  Tinsley Vance, PhD, APRN

    Specialty

    Hematology/Oncology

    4.9 (64)
    Cydney  Warfield, APRN

    Specialty

    Hematology/Oncology

    4.8 (240)